Xlife Sciences raised new capital

The Zurich-based Xlife Sciences AG has successfully raised 6 million Swiss francs as part of a capital increase. Both new and existing investors subscribed to shares with a total value of 6.02 million Swiss francs as part of this capital measure, which was concluded at the start of December, as detailed in a press release.

CEO of Xlife, Oliver R. Baumann, believes this represents confirmation of the appeal of the business model: “The strong interest of investors shows that our company, with its strategy of holding and developing a broad portfolio of early-stage life science projects is an attractive investment even in challenging times such as the corona crisis”. In this way, the business model is also seen as “an attractive investment stage diversification” by investors that have already invested in life sciences companies.

Xlife invests in the value development of highly promising life sciences technologies and therapies. In so doing, Xlife focuses on proof on concept studies for companies from the biotech sector. These represent a milestone in the two early phases prior to clinical trials, namely the invention disclosure and the preclinical phase. Through this approach, Xlife offers a “comparatively above average success rate for the biotech sector”, according to the company website.